These efforts, combined with improved financial performance, led to credit rating upgrades, with Acuité raising its rating by four notches to B+ (Stable Outlook) and CARE Ratings assigning a BB- (Stable Outlook).

Today's customers are more informed, and regulatory expectations for quality are higher than ever. Given these factors, I believe the Indian pharmaceutical industry is set for continued growth and global leadership, states Krishna Raghunathan, CFO of Supriya Lifescience Ltd.

The stock gave multibagger returns of 575 per cent in 3 years and a whopping 6,825 per cent in 5 years.

The shares of the company have a PE of 300x, an ROE of 3 per cent and an ROCE of 7 per cent.

The stock is up by 3.4 per cent from its 52-week low of Rs 44.50 per share

The stock gave multibagger returns of 197 per cent from its 52-week low of Rs 123 per share.

The stock gave multibagger returns of 136 per cent from its 52-week low of Rs 93.05 per share.

The stock is up by 6.6 per cent from its 52-week low of Rs 43 per share and a whopping 1,500 per cent in 5 years.

The stock gave multibagger returns of 350 per cent in just 3 years whereas BSE Sensex Index is up by 34 per cent.